Sign In
Buy BMRN
$60.02
-0.560 (-0.92%)
At Close: Jul 31, 2026
BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET
09:00am, Thursday, 30'th Jul 2026
SAN RAFAEL, Calif., July 30, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a confe
Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for
11:03am, Monday, 27'th Jul 2026
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ReNU syndrome was discovered in 2024 and there are no medicines approved for the condition Collaboration combines BioMarin's leadership in genetic medicines with n-Lorem's pioneering antisense experti
Bank of New York Mellon Corp Sells 631,362 Shares of BioMarin Pharmaceutical Inc. $BMRN
03:39am, Thursday, 23'rd Jul 2026
Bank of New York Mellon Corp decreased its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 35.5% in the first quarter, according to the company in its most recent 13F filing with
BioMarin: Commercial Infrastructure Is The Hidden Growth Asset
07:30am, Wednesday, 22'nd Jul 2026
BioMarin: Commercial Infrastructure Is The Hidden Growth Asset
D.A. Davidson & CO. Acquires 36,293 Shares of BioMarin Pharmaceutical Inc. $BMRN
04:21am, Tuesday, 21'st Jul 2026
D.A. Davidson and CO. boosted its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 467.1% during the first quarter, according to the company in its most recent filing with the Secu
FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo
11:46am, Tuesday, 14'th Jul 2026
BioMarin's FDA filing for full Voxzogo approval in achondroplasia has been accepted, with a regulatory decision expected by Feb. 28, 2027.
Application based on long-term safety and efficacy data from three ongoing studies, including adult height and additional clinical outcomes beyond linear growth, including body proportionality and arm
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
10:41am, Wednesday, 01'st Jul 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026
09:05am, Tuesday, 16'th Jun 2026
Data from an investigator-led study showed treatment with VOXZOGO resulted in sustained improvements in growth over three years in children with hypochondroplasia New Phase 1 results also presented fo
BioMarin (BMRN) Up 0.2% Since Last Earnings Report: Can It Continue?
12:30pm, Wednesday, 03'rd Jun 2026
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
BioMarin's Voxzogo Meets Goal in Late-Stage Study for Hypochondroplasia
02:26pm, Thursday, 21'st May 2026
BMRN's shares rise after Voxzogo hits the main goal in a late-stage hypochondroplasia study, supporting planned FDA filings in 2026.
BioMarin Reveals Dwarfism Study Data, Stock Soars
02:11pm, Thursday, 21'st May 2026
BioMarin Pharmaceuticals Inc. (NASDAQ:BMRN) stock is trading higher on Thursday as the company is celebrating positive results from its Phase 3 CANOPY-HCH-3 study for VOXZOGO (vosoritide) in children
BioMarin's drug shows significant growth gains in children in late-stage trial
05:20pm, Wednesday, 20'th May 2026
BioMarin Pharmaceutical said on Wednesday its treatment for a rare condition that leads to short stature helped boost growth in children, meeting the main goal of a late-stage study and sending
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia
04:20pm, Wednesday, 20'th May 2026
Study met primary endpoint, exceeding expectations with a highly statistically significant improvement in annualized growth velocity (AGV, change from baseline) of 2.33 cm/yr compared to placebo at we
